Blastomycosis

Overview

Blastomycosis is an endemic fungal infection caused mainly by Blastomyces dermatitidis and related species. Infection begins when microscopic spores are inhaled from disturbed soil or organic material. In the lungs the organism converts to a yeast form and can produce pneumonia ranging from mild illness to severe acute respiratory distress. Some infected people remain asymptomatic. ^{[1] [2]}

The immune response and fungal burden determine whether exposure produces illness. Pulmonary infection can resolve, persist or disseminate through the bloodstream. Skin is a classic extrapulmonary site, but bone, joints, the genitourinary system and the central nervous system can also be involved. People with impaired cellular immunity are more likely to develop severe or disseminated disease. ^{[1] [2]}

Blastomycosis is important because it often looks like ordinary community-acquired pneumonia. Patients may receive antibacterial treatment before fungal disease is considered, especially when travel or residence in an endemic region is not recognized. A history of soil exposure, outdoor work, excavation, hunting, forestry or residence near endemic waterways can increase diagnostic suspicion but is not required. ^{[1] [2] [3]}

Symptoms and warning signs

Symptoms often begin weeks after exposure and may include fever, cough, shortness of breath, chest pain, night sweats, fatigue, weight loss and muscle or joint pain. Skin disease can appear as verrucous, crusted or ulcerated lesions. Bone involvement can cause focal pain or swelling. Because these manifestations are nonspecific, clinical context and testing are needed to distinguish blastomycosis from bacterial pneumonia, tuberculosis, cancer and other fungal infections. ^{[1] [2]}

Severe shortness of breath, low oxygen levels, rapidly progressive pneumonia, confusion, meningitis-type symptoms or signs of sepsis require urgent assessment. Immunocompromised people and patients with central nervous system involvement need especially rapid specialist care because severe blastomycosis can be fatal without appropriate antifungal treatment. ^{[1] [2]}

Diagnosis

Diagnosis typically combines imaging with direct evidence of the fungus. Chest radiographs or CT can show infiltrates, nodules, masses or other abnormalities but are not specific. Samples may include sputum, bronchoalveolar lavage fluid, tissue from skin or lung lesions, or other involved sites. Microscopy and culture can establish the diagnosis, although culture may take time. ^{[1] [2]}

Urine or serum antigen testing can support the diagnosis and may return faster than culture, but cross-reactivity with Histoplasma can occur. Pathology can show broad-based budding yeast. When disease is severe or disseminated, clinicians evaluate other organ systems and may sample skin, bone, cerebrospinal fluid or other tissue depending on symptoms. Species identification and susceptibility testing are not required in every uncomplicated case but can matter in unusual disease. ^{[1] [2] [3]}

The differential diagnosis includes bacterial pneumonia, histoplasmosis, coccidioidomycosis, tuberculosis, lung cancer and inflammatory lung disease. Cutaneous lesions can mimic squamous-cell carcinoma or other chronic infections. The combination of a compatible geographic exposure, persistent pneumonia and characteristic skin lesions is a useful clue but still requires laboratory confirmation when feasible. ^{[2] [3]}

Causes, risk factors and clinical context

Anyone in an endemic region can be infected, but outdoor exposure to soil and decaying vegetation increases the chance of inhaling spores. Severe disease is more likely in people with weakened immune systems, including some transplant recipients, people receiving immunosuppressive therapy and those with advanced immune deficiency. Pregnancy can also influence management because some antifungal drugs are inappropriate during pregnancy. ^{[1] [2]}

About half of infected people may have no symptoms. Symptomatic pulmonary disease can persist for weeks or months, and some cases become chronic. Dissemination can occur even when lung symptoms are not dramatic. Because illness can mimic more common diseases, diagnostic delay is a recurring problem and may lead to more advanced disease before effective therapy is started. ^{[1] [2] [3]}

Complications and why the diagnosis matters

Complications include acute respiratory distress syndrome, chronic pulmonary damage, dissemination to skin or bone and central nervous system infection. Osteoarticular disease can require prolonged treatment. CNS blastomycosis is uncommon but serious because meningitis or brain lesions may cause neurologic disability and require different antifungal choices and longer treatment. ^{[1] [2]}

Most appropriately treated patients recover, although therapy is prolonged and relapse is possible if treatment is too short or immune suppression persists. Severe respiratory failure and disseminated disease carry substantially greater risk. Follow-up is based on symptoms, organ involvement and response to antifungal therapy rather than a single test result. ^{[1] [2] [3]}

Treatment and management

Mild-to-moderate blastomycosis is commonly treated with an oral azole antifungal, most often itraconazole. Moderate-to-severe, central nervous system or life-threatening disease generally requires initial amphotericin B, followed by prolonged oral therapy once the patient is stable. The exact regimen and duration depend on disease severity, immune status, organ involvement and drug interactions. ^{[1] [2]}

Patients with severe pneumonia may need oxygen, intensive-care support or mechanical ventilation. Drug monitoring is important because azoles interact with many medicines and can affect the liver, while amphotericin B can affect kidney function and electrolytes. Treatment often lasts many months, so adherence and monitoring are part of the therapeutic plan. ^{[1] [2] [3]}

Antifungal treatment should not be started or changed solely from an online description because the drugs have important interactions, pregnancy considerations and organ-specific toxicity. Persistent pneumonia that does not respond as expected to antibiotics should prompt diagnostic reconsideration rather than repeated empiric antibacterial courses without reassessment. ^{[1] [2]}

Follow-up, recovery and prevention

Clinical improvement in fever, respiratory symptoms, skin lesions and energy is used to judge response. Imaging may be repeated in pulmonary disease, especially when abnormalities were extensive. Patients with disseminated disease need site-specific follow-up, and immunocompromised people may require longer treatment or secondary prevention depending on the underlying condition. ^{[1] [2]}

There is no vaccine. Avoiding all exposure is difficult because the fungus is environmental, but people at high risk for severe infection can reduce activities that heavily disturb soil in endemic areas when feasible. Public-health awareness and earlier testing are important because prevention through complete environmental avoidance is not practical for most people. ^{[1] [2] [3]}

Special situations and care pathway

Pregnancy, transplantation, advanced immune suppression and central nervous system disease change the risk-benefit balance of antifungal therapy. Some azole drugs are avoided in pregnancy, while severe maternal disease may still require amphotericin B. Specialist infectious-disease consultation is appropriate for complicated disease, relapse, CNS involvement or major drug-interaction concerns. ^{[1] [2] [3]}

A useful care pathway is to suspect fungal pneumonia when symptoms persist in a compatible region, obtain chest imaging, choose appropriate fungal testing, identify extrapulmonary sites, and classify disease as mild, severe or disseminated. Treatment intensity and duration follow that classification, with ongoing monitoring for toxicity and relapse. ^{[1] [2]}

When to seek urgent medical care

Urgent evaluation is appropriate for severe breathlessness, oxygen desaturation, rapidly worsening pneumonia, confusion, severe headache or neck stiffness, signs of shock or serious illness in an immunocompromised patient. These findings can indicate ARDS, CNS involvement or disseminated infection. ^{[1] [2]}

Sources

1. CDC — Clinical Overview of Blastomycosis
2. CDC — Blastomycosis Basics
3. Infectious Diseases Society of America — Clinical Practice Guideline for the Management of Blastomycosis

This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.